Medical tests

Psomagen Inc. Expands Its COVID-19 Diagnostic Services to Include At-Home Saliva Collection Kits

Retrieved on: 
Wednesday, July 7, 2021
MEN, General Health, Family, Specialty, Consumer, Infectious diseases, Genetics, Retail, Biotechnology, Women, Medical Supplies, Seniors, Health, Medicine, Coronaviridae, Infectious diseases, COVID-19 testing, COVID-19, Medical tests, Curative, DiaSorin, MEN, General Health, Family, Specialty, Consumer, Infectious diseases, Genetics, Retail, Biotechnology, Women, Medical Supplies, Seniors, Health, Medicine, Coronaviridae, Infectious diseases, COVID-19 testing, COVID-19, Medical tests, Curative, DiaSorin

Psomagen, Inc ., a CLIA-certified genetic analysis service provider, is adapting to the publics changing COVID-19 testing needs by expanding its SARS-CoV-2 diagnostic services.

Key Points: 
  • Psomagen, Inc ., a CLIA-certified genetic analysis service provider, is adapting to the publics changing COVID-19 testing needs by expanding its SARS-CoV-2 diagnostic services.
  • In addition to its GutBiome and Gene Trait testing, the company now offers direct-to-consumer saliva collection kits for diagnosing COVID-19 for adults age 18 and older.
  • Psomagen offers two other EUA-authorized SARS-CoV-2 tests including the saliva-based SalivaDirect diagnostic test and the swab-based Psoma COVID-19 RT Coronavirus Test .
  • Psomagen, Inc. , formerly Macrogen USA, delivers genetic sequencing services to the clinical, academic, and consumer markets.

BiologyWorks Awarded ISO 13485:2016 Certification for Development of its SARS-CoV-2 Fast Molecular Reusable Diagnostic Test

Retrieved on: 
Tuesday, July 6, 2021
Infectious diseases, Biotechnology, Health, Medical devices, Branches of biology, Biotechnology, Medicine, Clinical medicine, Biomarkers, Chemical pathology, Medical device, Medical tests, Molecular diagnostics, Cepheid

BiologyWorks , a medical test developer with a mission to deliver fast and accurate molecular testing, today announced that it has earned (ISO) 13485:2016 certification for its quality management processes in medical device manufacturing.

Key Points: 
  • BiologyWorks , a medical test developer with a mission to deliver fast and accurate molecular testing, today announced that it has earned (ISO) 13485:2016 certification for its quality management processes in medical device manufacturing.
  • BiologyWorks is the developer of the BiologyWorks k(now) test, a fast molecular test for qualitative detection of pathogens and molecular biomarkers for SARS-CoV-2 and other viruses and infections.
  • Our focus remains on fast-tracking our molecular technology to deliver testing that is fast, private, affordable, and effective.
  • This certification adds to BiologyWorks existing CE IVD European Council Directive 98/79/EC certification for manufacturers of in vitro diagnostic medical devices in the European Union.

RamSoft Acquires a Majority Stake in Meddiff to Advance Patient Care Globally

Retrieved on: 
Tuesday, July 6, 2021
Medical imaging, Medicine, Medical physics, Breast imaging, Cancer screening, Mammography, Projectional radiography, Workflow, Radiology, Clinical medicine, Medical tests

RamSoft will continue to be headquartered in Toronto, Canada and the company's management team will be led by President and CEO Vijay Ramanathan.

Key Points: 
  • RamSoft will continue to be headquartered in Toronto, Canada and the company's management team will be led by President and CEO Vijay Ramanathan.
  • "Our commitment to saving patient lives through universal access to imaging is what drives us as a company.
  • To expand its global footprint and support this mission, RamSoftlooked towards Meddiff, a Bangalore-based company that has over 1,500 installed sites globally.
  • Built using cutting-edge, single database technology, our radiology, mammography, and enterprise imaging software enables practices tooptimize their workflow, cut costs, and overall, improve patient care.

RamSoft Acquires a Majority Stake in Meddiff to Advance Patient Care Globally

Retrieved on: 
Tuesday, July 6, 2021
Medical imaging, Medicine, Medical physics, Breast imaging, Cancer screening, Mammography, Projectional radiography, Workflow, Radiology, Clinical medicine, Medical tests

RamSoft will continue to be headquartered in Toronto, Canada and the company's management team will be led by President and CEO Vijay Ramanathan.

Key Points: 
  • RamSoft will continue to be headquartered in Toronto, Canada and the company's management team will be led by President and CEO Vijay Ramanathan.
  • "Our commitment to saving patient lives through universal access to imaging is what drives us as a company.
  • To expand its global footprint and support this mission, RamSoftlooked towards Meddiff, a Bangalore-based company that has over 1,500 installed sites globally.
  • Built using cutting-edge, single database technology, our radiology, mammography, and enterprise imaging software enables practices tooptimize their workflow, cut costs, and overall, improve patient care.

Seegene announces partnership with Bio-Rad to develop diagnostic testing products for the U.S. Market

Retrieved on: 
Tuesday, July 6, 2021
Medical tests, Bio-Rad Laboratories, Molecular diagnostics, Life sciences, Companies, Medicine, DiaSorin

A significant step forward for Seegene in expanding its business to the U.S., the world's biggest in vitro diagnostics market.

Key Points: 
  • A significant step forward for Seegene in expanding its business to the U.S., the world's biggest in vitro diagnostics market.
  • SEOUL, South Korea, July 6, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), aSouth Korean leading biotechnology firmhas signed a partnership agreementwith American biotechnology companyBio-Rad Laboratories, Inc.tosupport entering theU.S.market.
  • Seegene announcedon July 1 that it has signed a partnership with Bio-Rad, laboratories, Inc. for the clinical development and commercialization of infectious disease molecular diagnostic products.
  • This new partnership is expected to streamline the process for Seegeneto seek U.S.FDA clearance and the partnership of thetwoworldclasscompaniesis expected to drive new U.S. market opportunity.

Seegene announces partnership with Bio-Rad to develop diagnostic testing products for the U.S. Market

Retrieved on: 
Tuesday, July 6, 2021
Medical tests, Bio-Rad Laboratories, Molecular diagnostics, Life sciences, Biology, Science and technology

A significant step forward for Seegene in expanding its business to the U.S., the world's biggest in vitro diagnostics market.

Key Points: 
  • A significant step forward for Seegene in expanding its business to the U.S., the world's biggest in vitro diagnostics market.
  • SEOUL, South Korea, July 6, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), aSouth Korean leading biotechnology firmhas signed a partnership agreementwith American biotechnology companyBio-Rad Laboratories, Inc.tosupport entering theU.S.market.
  • Seegene announcedon June1 that it has signed a partnership with Bio-Rad, laboratories, Inc. for the clinical development and commercialization of infectious disease molecular diagnostic products.
  • This new partnership is expected to streamline the process for Seegeneto seek U.S.FDA clearance and the partnership of thetwoworldclasscompaniesis expected to drive new U.S. market opportunity.

The Global Specimen Validity Test Reagents Market is Projected to Grow at a CAGR of 7% to 2029 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 6, 2021
Other Science, Science, Articles, Learning, Skills, Medical tests, Drug control law, Drug test, Tests, Workplace, Validity, Reagent, Test market

The Global Specimen validity test reagents market is projected to grow at a CAGR of 7 %.

Key Points: 
  • The Global Specimen validity test reagents market is projected to grow at a CAGR of 7 %.
  • Specimen validity testing (SVT) is performed on a urine drug screen specimen to detect substitution, adulteration, or dilution.
  • What is the key impact of Covid-19 over market revenues and market determinants in the Specimen validity test reagents market?
  • Who are the key players in the Specimen validity test reagents market and what are their key product categories and strategies?

Global COVID-19 Diagnostics Market (2020 to 2025) - by Technology, Product, Channel and Country - ResearchAndMarkets.com

Retrieved on: 
Monday, July 5, 2021
Infectious diseases, Health, Medical devices, DiaSorin, Natural sciences, Chemistry, Physical sciences, Ruo, Luminex, Assay, Medical tests

5.3 Novacyt Gets CE Mark for Multigene SARS-CoV-2 Test, Launches RUO Variant Assay

Key Points: 
  • 5.3 Novacyt Gets CE Mark for Multigene SARS-CoV-2 Test, Launches RUO Variant Assay
    5.5 Phosphorus Diagnostics Gets EUA for DTC C19 Test, Sample Collection Kit
    5.9 DiaSorin Acquires Luminex to Broaden MDx Portfolio, Expand US Presence
    5.16 FDA Grants EUAs for DTC Sample Collection Kit, Two Molecular Tests
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210705005157/en/

Global High Content Screening Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts

Retrieved on: 
Friday, July 2, 2021
Natural sciences, Physical sciences, Drug discovery, Chemistry, Microscopy, Laboratory techniques, High-content screening, Medical tests, Screening, Markets.com, HCS, Cellomics

DUBLIN, July 2, 2021 /PRNewswire/ -- The "High Content Screening Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 2, 2021 /PRNewswire/ -- The "High Content Screening Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • High content screening (HCS), or high content analysis, refers to an analytical method of automated microscopy that uses visualization tools to obtain quantitative data from cell populations.
  • What has been the impact of COVID-19 on the global high content screening market?
  • What is the structure of the global high content screening market and who are the key players?

United States In Vitro Diagnostics Market Report 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 1, 2021
Biotechnology, Health, Medical devices, Alternatives to animal testing, In vitro, IVD, Medical tests, Companies, Science, DiaSorin, Natural sciences, Cepheid

The "United States In Vitro Diagnostics Market, Impact of COVID-19, Industry Trends, Growth, Opportunity Company Overview, Sales Analysis, Forecast" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States In Vitro Diagnostics Market, Impact of COVID-19, Industry Trends, Growth, Opportunity Company Overview, Sales Analysis, Forecast" report has been added to ResearchAndMarkets.com's offering.
  • In the United States, the growing prevalence of chronic and infectious diseases has spurred the development of the in-vitro diagnostics (IVD) market.
  • Besides, the United States In-Vitro Diagnostic market is broad and has various types of diagnostics instruments to perform different techniques.
  • In the United States, the In-vitro diagnostics market is currently in the South of the country, followed by the West being second.